Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

Research & Clinical Trials
Toggle Menu

NCT00989651

Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Study identifier: NCT00989651
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Histologically confirmed newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cancer stage II-IV. More than 5 years since prior chemotherapy for abdominal or pelvic tumor, (prior chemotherapy for localized breast cancer allowed if more than 3 years ago and patient is free of metastatic disease)
  • Stage II-IV disease defined surgically with either optimal (≤ 1 cm) or suboptimal residual disease
    Has undergone initial surgery for diagnosis, staging, and cytoreduction within the past 1-12 weeks

Type of study:

Phase I

Treatment:

Patients are randomized to one of two groups. 

  • The first group receives paclitaxel, carboplatin, and bevacizumab on day one, Veliparib twice daily for 21 days, treatment repeats for 16 courses.
  • The second group receives carboplatin, and bevacizumab on day one, paclitaxel once a week, and Veliparib twice daily for 21 days, treatment repeats for 16 courses

Study sites:

Colorado
Aurora
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Contact: Susan A. Davidson 720-848-0650

Georgia
Augusta
Georgia Health Sciences University
Augusta, Georgia, United States, 30912
Contact: Sharad A. Ghamande 706-721-1663 cancer@georgiahealth.edu

Iliinois
Chicago
University of Chicago Comprehensive Cancer Center
Contact: Seiko D. Yamada 773-834-7424

Iowa
Iowa City
University of Iowa Hospitals and Clinics
Contact: Koen DeGeest 800-237-1225

Maryland
Baltimore
Johns Hopkins University Recruiting
Contact: Deborah K. Armstrong 410-955-8804 jhcccro@jhmi.edu

Missouri
St. Louis
Washington University School of Medicine
Contact: David G. Mutch 800-600-3606 info@ccadmin.wustl.edu

New York
New York
Memorial Sloan Kettering Cancer Center
Contact: Katherine M. Bell-McGuinn 212-639-7202

Ohio
Cleveland
Case Western Reserve University
Contact: Steven E. Waggoner 800-641-2422

Cleveland
Cleveland Clinic Foundation
Contact: Steven E. Waggoner 800-641-2422

Cleveland
MetroHealth Medical Center
Contact: Peter G. Rose 866-223-8100

Mayfield Heights
Hillcrest Hospital Cancer Center Recruiting
Contact: Steven E. Waggoner 800-641-2422

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center
Contact: Robert S. Mannel 405-271-4272 julie-traylor@ouhsc.edu

Pennsylvania
Philadelphia
Fox Chase Cancer Center Recruiting
Contact: Lainie P. Martin 215-728-4790

Rhode Island
Providence
Women and Infants Hospital Recruiting
Contact: Carolyn K. McCourt 401-274-1122

Virginia
Charlottesville
University of Virginia
Contact: Linda R. Duska 434-243-6143
Principal Investigator: Linda R. Duska

Richmond
Virginia Commonwealth University Recruiting
Contact: Andrew Poklepovic 804-628-1939

Page updated 06/09/13